Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps is his Department is taking to ensure brain tumour patients have timely access to whole genome sequencing.

Genomic testing is delivered through the NHS Genomic Medicine Service via seven regional NHS Genomic Laboratory Hubs (NHS GLHs). Testing follows the National Genomic Test Directory, which includes whole genome sequencing (WGS) for neurological tumours, including primary brain cancers. NHS England has produced national sample handling guidance for WGS of solid tumours, including brain tumours, to maintain DNA quality and improve access to WGS by standardising the collection, processing, and transport of samples. Approaches to the handling of fresh tissue have also been reviewed to speed up processes. In 2025/26, NHS England is continuing its Cancer Genomics Improvement Programme to deliver quality improvement initiatives, education, local engagement, and the establishment of Cellular Pathology Genomic Centres to streamline cancer genomics pathways and accelerate genomic testing. These approaches are addressing variability and ensuring equitable regional access to WGS for brain tumour patients. NHS England monitors performance through Patient Level Contract Monitoring data and works with NHS GLHs to address variation and drive improvements.